All-cause mortality rates are more than three-fold higher in patients with schizophrenia, including a three-fold increased risk of death from Type 2 diabetes and a two-fold increased risk of death from cardiovascular disease. A new clinical trial published in JAMA Psychiatry provides strong evidence that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that is given once a week, may help control metabolic risk factors in patients who are at high risk.

People with schizophrenia have a far shorter life expectancy than the normal population, frequently by 15 years. The main reasons for this big difference are cardiovascular disease and obesity-related Type 2 diabetes. While modifiable factors such as diet and physical inactivity play a role, second-generation antipsycho

See Full Page